Kernal Bio is a biotech company developing mRNA 2.0 immunotherapies. Kernal mines translatome data to discover cell-specific sequence features and design mRNAs that are selectively translated in cancer cells. These mRNAs are formulated with proprietary, best-in-class LNPs validated in non-human primates (NHPs). Our development candidates have a remarkably wide therapeutic index (100x) and can be systemically delivered with extrahepatic LNPs. Lead program shows high efficacy and safety in solid tumors resistant to all other immuno-oncology agents and is tolerated well in NHPs. With roots at MIT, Harvard, Merck, and BMS, Kernal’s management team has deep expertise in mRNA therapeutics with three FDA approvals and 120+ patents. Based in Cambridge, MA, the company is backed by Hummingbird Ventures, Amgen Ventures, HBM Partners, NASA, and Boeing.